

Getting started with TAZVERIK® (tazemetostat)

TAZVERIK is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

Important Safety Information

What is the most important information I should know about TAZVERIK?

TAZVERIK can cause serious side effects, including:

• **Risk of new cancers.** An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

Please see additional Important Safety Information throughout this brochure and refer to the full <u>Prescribing Information</u>, including Patient Medication Guide.

Your guide to treatment with TAZVERIK

Your doctor may have recommended TAZVERIK to help treat your epithelioid sarcoma. You may find it helpful for you and those involved in your care to learn more about your treatment and what to expect while taking TAZVERIK.

Table of contents:

Page 3	What should I know about epithelioid sarcoma?
Page 4	What is TAZVERIK and how does it work?

- Page 5 What are the possible results and side effects of TAZVERIK?
- Page 6 What important information should I know before and while taking TAZVERIK?
- Page 7 How do I take TAZVERIK?
- Pages 8 EpizymeNOW Patient & Product Support
- Pages 9 & 10 Notes

Selected Important Safety Information

Before taking TAZVERIK, tell your healthcare provider if you are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Females who are able to become pregnant should use effective non-hormonal birth control during treatment and for 6 months after the final dose of TAZVERIK. Males with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.

Please see additional Important Safety Information throughout this brochure and refer to the full <u>Prescribing Information</u>, including Patient Medication Guide.

You can also learn more at <u>TAZVERIK.com/espatient</u> or call EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday through Friday (9 AM - 6 PM ET).


What should I know about epithelioid sarcoma?

There is a lot to know about epithelioid sarcoma, and you might be feeling overwhelmed. Here are some basic facts to help you get a better understanding of epithelioid sarcoma.

Epithelioid sarcoma is a rare type of soft tissue cancer. It most often starts as a hard, sometimes painless lump in tissues under the skin of a finger, hand, forearm, lower leg, or foot, though it can start in other areas of the body as well. Sometimes, epithelioid sarcoma appears as skin ulcers that do not heal. These could look like open wounds over the growths.

There are two types of epithelioid sarcoma:

- **Distal-type:** The more typical form that often occurs away from the center of the body, near the limbs (arms, legs, hands, and feet).
- **Proximal-type:** A rare form that tends to be more aggressive and occurs near the center of the body (i.e. torso, pelvic area, and genitals).



Working with a healthcare professional who specializes in treating soft tissue sarcomas may give you a better understanding of your disease. Talk with your doctor about the right treatment option for you.



What is TAZVERIK and how does it work?

TAZVERIK is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

TAZVERIK is an oral, twice-daily treatment that works differently from other cancer treatments

- TAZVERIK is not a chemotherapy treatment and does not kill cancer cells directly.
- A protein called EZH2 is found in many cells in the body. When there is increased activity, it can lead to tumor growth. TAZVERIK is the first type of therapy that was designed to target and block EZH2.



What are the possible results and side effects of TAZVERIK?

What were the results of the study?

Every individual is different and may respond differently. In a clinical study specifically for epithelioid sarcoma:

of patients (n=9/62) had an overall response*t to TAZVERIK (meaning the cancer either reduced in size by at least 30% or completely disappeared)

of patients (n=1/62) had a complete response (meaning their target tumors completely disappeared)

of patients (n=8/62) had a partial response (meaning their target tumors reduced in size by at least 30%)

*The overall response is the sum of partial responses and complete responses. [†]The time to tumor shrinkage in the clinical trial ranged from around 1 month to around 18 months.

What are the possible side effects of TAZVERIK?

It is important that you are informed about the potential side effects during treatment with TAZVERIK. Talk to your doctor about concerns you may have.

TAZVERIK can cause serious side effects, including:

• Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if vou are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

These are not all the possible side effects of TAZVERIK. Call your doctor for medical advice about side effects.

The most common side effects of TAZVERIK in people with epithelioid sarcoma include:

- Pain
- Tiredness
- Nausea
- Decreased appetite
- Vomiting
- Constipation

Please see additional Important Safety Information throughout this brochure and refer to the full Prescribing Information, including Patient Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.



What important information should I know before and while taking TAZVERIK?

What should I tell my healthcare provider before taking TAZVERIK?

Tell your healthcare provider about all your medical conditions, including if you:

- Are pregnant or plan to become pregnant. TAZVERIK can harm your unborn baby. Your healthcare provider will give you a pregnancy test before you start treatment with TAZVERIK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
- Females who are able to become pregnant should use effective non-hormonal birth control (such as condoms) during treatment and for 6 months after the final dose of TAZVERIK. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with TAZVERIK. Talk to your healthcare provider about birth control options that are right for you.
- **Males** with female partners who are able to become pregnant should use effective birth control during treatment and for 3 months after the final dose of TAZVERIK.
- Are breastfeeding or plan to breastfeed. It is not known if TAZVERIK passes into your breast milk. Do not breastfeed during treatment and for 1 week after the final dose of TAZVERIK.

Tell your healthcare provider about all the medicines you take,

including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAZVERIK may affect the way other medicines work and other medicines may affect how TAZVERIK works.

What should I avoid while taking TAZVERIK?

- Avoid eating grapefruit or drinking grapefruit juice during treatment with TAZVERIK.
- Avoid taking St. John's wort during treatment with TAZVERIK.

Talk to your healthcare provider before starting any new medications or supplements.

General information about the safe and effective use of TAZVERIK

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TAZVERIK for a condition for which it was not prescribed. Do not give TAZVERIK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAZVERIK that is written for health professionals.

How do I take TAZVERIK?

What is the recommended dose?

The recommended dosing is 4 tablets (200 mg each), twice daily. Your doctor will confirm what your dose should be, as some patients need a different dose.

How to take TAZVERIK



Take TAZVERIK exactly as your healthcare provider tells you.

Take TAZVERIK 2 times each day.

Your healthcare provider may change your dose, temporarily stop, or completely stop treatment with TAZVERIK if you get certain side effects.



Each tablet should be swallowed whole. Do not cut, crush, or chew TAZVERIK tablets. You can take TAZVERIK with or without food.

NDC 72607-100-00 240 Tablets

TAZVERIK

Epizyn

Not actual size.

If you miss a dose or vomit after taking your dose, just skip that dose and take the next dose at your regular time.

It is important to keep your doctor informed of any changes during your treatment and to follow your treatment regimen as instructed.

Please see additional Important Safety Information throughout this brochure and refer to the full <u>Prescribing Information</u>, including Patient Medication Guide.



EpizymeNOW Patient & Product Support

To help facilitate access to TAZVERIK for patients with a valid prescription, EpizymeNOW Patient & Product Support can help you understand your insurance coverage and identify any financial or product support that may be available to you. Below is a list of support programs for which you may be eligible:



PATIENT ASSISTANCE PROGRAM (PAP):

You may be eligible to receive a limited supply of free medication if you have limited or no coverage for TAZVERIK.



QUICK START PROGRAM:

You may be eligible to receive a limited supply of free medication if you are experiencing a delay in the coverage of TAZVERIK.



BRIDGE SUPPLY PROGRAM:

You may be eligible to receive a limited supply of free medication if you are experiencing an unexpected change in your prescription drug coverage.



CO-PAY ASSISTANCE PROGRAM:

You may be eligible to receive co-payment assistance from Epizyme for TAZVERIK if you are responsible for a co-payment for your medication under your commercial (private) drug insurance plan.*

*This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state healthcare program. Limitations apply. Void where prohibited.



If you have questions, you can visit <u>www.epizymenow.com</u> or contact EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday through Friday (9 AM - 6 PM ET).

Notes



TAZVERIK[®] (tazemetostat)

TAZVERIK is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.

The approval of TAZVERIK in these patients is based on a study that measured the percentage of patients whose tumor shrank or disappeared after treatment and how long that response lasted. TAZVERIK is still being studied to confirm these benefits.

It is not known if TAZVERIK is safe and effective in children less than 16 years of age.

- TAZVERIK is the **first and only** FDA-approved therapy specifically studied in epithelioid sarcoma patients.
 - ^o Studied in the largest, global trial for epithelioid sarcoma patients (N=62).
- It is an oral medication, taken twice daily with or without food.
- Financial assistance or other patient support programs may be available to eligible patients through EpizymeNOW Patient & Product Support.

More questions?

Talk to your doctor or visit <u>TAZVERIK.com/espatient</u> to learn more. You can visit <u>www.epizymenow.com</u> or contact EpizymeNOW Patient & Product Support at 1-833-4EPINOW (437-4669), Monday through Friday (9 AM - 6 PM ET).

Selected Important Safety Information

Serious side effects: Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.

If you are pregnant, TAZVERIK can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. You should use effective non-hormonal birth control during and after use of TAZVERIK.

Please see additional Important Safety Information throughout this brochure and refer to the full <u>Prescribing Information</u>, including Patient Medication Guide.



TAZVERIK is a registered trademark of Epizyme, Inc. , an Ipsen company. © 2023 Ipsen Biopharmaceuticals, Inc. All Rights Reserved. 05/23 TAZ-US-000463

Notes